IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hiroaki ITO et al.

Title:

A PREVENTIVE OR

THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING IL-6 ANTAGONIST AS AN ACTIVE

INGREDIENT

Appl. No.:

10/677,227

Filing Date:

10/3/2003

Examiner:

Prema Maria MERTZ

Art Unit:

1646

Confirmation

8597

Number:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present

application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facle art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

Fees in the amount of \$180.00 in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit

card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Stephen B. Maebius Attorney for Applicant

Registration No. 35,264

Date

FOLE W& LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

HCW/SBM/ARSC:kdm

Attachment: Form PTO/SB/08

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	ir form 1449/	PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			SURE	Application Number	10/877,227	
			CANT	Filing Date	10/3/2003	
	Onto Culturation time 4, 2007			First Named Inventor	Hiroaki ITO	
Date Submitted: June 1, 2007			, 2007	Art Unit	1646	***************************************
THE PARTY OF THE P	(use as many si	heets as ne	cessary)	Examiner Name	Prema Maria MERTZ	
Sheet	1	of	1	Attorney Dockel Number	053466-0365	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Refevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
		Volenkar dan Anno era kanan era era			

		UNPUBLISH	ED U.S. PATENT AP	PLICATION DOCUMENTS	
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code* (# known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Gited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

			FOREIGN PATENT DI	OCUMENTS '		
Examiner initials*	Cite No.1	Foreign Patent Document Country Code "Number" Kind Code (# #nown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Colorins, Lines, Where Rolevant Passages or Relevant Figures Appear	1
				A to Marie to the state of the Deministration of the State of the Stat		

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	+
		HARRISON, Paul, et. al., inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies, British Journal of Haemalology, 1996, pp. 443-451, Vol. 95, Blackwell Science Ltd., Oklahoma City, Oklahoma, USA.	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not obtain is in conformance with MPEP 809. Draw tine through district in conformance and not considered, include copy of this form with next communication to applicant. I Applicant's unique district designation aumber (optional), 2 See Kinds Codes of USPTO Parent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the involvation code (NIPO Standard ST,3). 4 For Japanese patent documents, the indication of the response must precode the sensil number of the patient document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

under WIPO Standard 5.T.16 if possible, 6 Applicant is to place a chock mark terplical templage Translation is attached.

This collection of information is required by 37 GFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 GFR 1.94. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for no the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you equire to complete into for processing this form end/or supportaints for reducing this burden, should be sent to the Chief Information Officer, U.S. Pattert and Trisdomark Officer, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patterts, P.O. Box 1450, Alexandria, VA 22313-1450.